Cite

HARVARD Citation

    Zimmer, L. et al. (2017). Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European journal of cancer. pp. 47-55. [Online]. 
  
Back to record